Plain-English translation of NCT06444009 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing three different immune-boosting medications—ivonescimab, cadonilimab, and penpulimab—each combined with standard chemotherapy drugs, given before surgery for advanced head and neck cancer. Researchers want to see if adding this medication to chemotherapy helps destroy more cancer cells before the tumor is surgically removed. After surgery, you would continue receiving the medication to help prevent the cancer from coming back.
Head and neck cancers that have spread to nearby tissues are difficult to treat with surgery alone. This study explores whether this medication, by strengthening the immune system to fight cancer cells, might improve outcomes when given alongside traditional chemotherapy before surgery.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combined with chemotherapy as an infusion every few weeks for three cycles (roughly 9 weeks) before your surgery. After your tumor is surgically removed, you would continue receiving the medication alone for 16 cycles to help prevent recurrence, with regular visits to monitor your health and watch for side effects. The entire study participation would span several months, with frequent clinic visits and blood tests.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China